These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

408 related items for PubMed ID: 27504914

  • 1. Efficacy and safety of adalimumab in Chinese patients with moderate-to-severe plaque psoriasis: results from a phase 3, randomized, placebo-controlled, double-blind study.
    Cai L, Gu J, Zheng J, Zheng M, Wang G, Xi LY, Hao F, Liu XM, Sun QN, Wang Y, Lai W, Fang H, Tu YT, Sun Q, Chen J, Gao XH, Gu Y, Teixeira HD, Zhang JZ, Okun MM.
    J Eur Acad Dermatol Venereol; 2017 Jan; 31(1):89-95. PubMed ID: 27504914
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial.
    Reich K, Armstrong AW, Foley P, Song M, Wasfi Y, Randazzo B, Li S, Shen YK, Gordon KB.
    J Am Acad Dermatol; 2017 Mar; 76(3):418-431. PubMed ID: 28057361
    [Abstract] [Full Text] [Related]

  • 3. Adalimumab for treatment of moderate to severe chronic plaque psoriasis of the hands and feet: efficacy and safety results from REACH, a randomized, placebo-controlled, double-blind trial.
    Leonardi C, Langley RG, Papp K, Tyring SK, Wasel N, Vender R, Unnebrink K, Gupta SR, Valdecantos WC, Bagel J.
    Arch Dermatol; 2011 Apr; 147(4):429-36. PubMed ID: 21173304
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial.
    Blauvelt A, Papp KA, Griffiths CE, Randazzo B, Wasfi Y, Shen YK, Li S, Kimball AB.
    J Am Acad Dermatol; 2017 Mar; 76(3):405-417. PubMed ID: 28057360
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of adalimumab among patients with moderate to severe psoriasis with co-morbidities: Subanalysis of results from a randomized, double-blind, placebo-controlled, phase III trial.
    Kimball AB, Bensimon AG, Guerin A, Yu AP, Wu EQ, Okun MM, Bao Y, Gupta SR, Mulani PM.
    Am J Clin Dermatol; 2011 Feb 01; 12(1):51-62. PubMed ID: 21110526
    [Abstract] [Full Text] [Related]

  • 6. Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial.
    Reich K, Gooderham M, Thaçi D, Crowley JJ, Ryan C, Krueger JG, Tsai TF, Flack M, Gu Y, Williams DA, Thompson EHZ, Paul C.
    Lancet; 2019 Aug 17; 394(10198):576-586. PubMed ID: 31280967
    [Abstract] [Full Text] [Related]

  • 7. Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extension.
    van de Kerkhof PC, Segaert S, Lahfa M, Luger TA, Karolyi Z, Kaszuba A, Leigheb G, Camacho FM, Forsea D, Zang C, Boussuge MP, Paolozzi L, Wajdula J.
    Br J Dermatol; 2008 Nov 17; 159(5):1177-85. PubMed ID: 18673365
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and safety of adalimumab every other week versus methotrexate once weekly in children and adolescents with severe chronic plaque psoriasis: a randomised, double-blind, phase 3 trial.
    Papp K, Thaçi D, Marcoux D, Weibel L, Philipp S, Ghislain PD, Landells I, Hoeger P, Kotkin C, Unnebrink K, Seyger M, Williams D.
    Lancet; 2017 Jul 01; 390(10089):40-49. PubMed ID: 28478975
    [Abstract] [Full Text] [Related]

  • 9. Adalimumab for nail psoriasis: Efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo-controlled trial.
    Elewski BE, Okun MM, Papp K, Baker CS, Crowley JJ, Guillet G, Sundaram M, Poulin Y, Gu Y, Geng Z, Williams DA, Rich PA.
    J Am Acad Dermatol; 2018 Jan 01; 78(1):90-99.e1. PubMed ID: 28993005
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials.
    Gordon KB, Strober B, Lebwohl M, Augustin M, Blauvelt A, Poulin Y, Papp KA, Sofen H, Puig L, Foley P, Ohtsuki M, Flack M, Geng Z, Gu Y, Valdes JM, Thompson EHZ, Bachelez H.
    Lancet; 2018 Aug 25; 392(10148):650-661. PubMed ID: 30097359
    [Abstract] [Full Text] [Related]

  • 11. Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal.
    Spuls PI, Hooft L.
    Br J Dermatol; 2012 Oct 25; 167(4):710-3; discussion 714-5. PubMed ID: 23013312
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis.
    Menter A, Gordon KB, Leonardi CL, Gu Y, Goldblum OM.
    J Am Acad Dermatol; 2010 Sep 25; 63(3):448-56. PubMed ID: 20605254
    [Abstract] [Full Text] [Related]

  • 13. Impact of immunogenicity on pharmacokinetics, efficacy and safety of adalimumab in adult patients with moderate to severe chronic plaque psoriasis.
    Mostafa NM, Nader AM, Noertersheuser P, Okun M, Awni WM.
    J Eur Acad Dermatol Venereol; 2017 Mar 25; 31(3):490-497. PubMed ID: 27545848
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and Safety of HLX03, an Adalimumab Biosimilar, in Patients with Moderate-to-Severe Plaque Psoriasis: A Randomized, Double-Blind, Phase III Study.
    Cai L, Li L, Cheng H, Ding Y, Biao Z, Zhang S, Geng S, Liu Q, Fang H, Song Z, Lu Y, Li S, Guo Q, Tao J, He L, Gu J, Yang Q, Han X, Gao X, Deng D, Li S, Wang Q, Zhu J, Zhang J.
    Adv Ther; 2022 Jan 25; 39(1):583-597. PubMed ID: 34816373
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of adalimumab when added to inadequate therapy for the treatment of psoriasis: results of PRIDE, an open-label, multicentre, phase IIIb study.
    Papp K, Ho V, Teixeira HD, Guerette B, Chen K, Lynde C.
    J Eur Acad Dermatol Venereol; 2012 Aug 25; 26(8):1007-13. PubMed ID: 22023702
    [Abstract] [Full Text] [Related]

  • 16. Adalimumab for nail psoriasis: efficacy and safety over 52 weeks from a phase-3, randomized, placebo-controlled trial.
    Elewski BE, Baker CS, Crowley JJ, Poulin Y, Okun MM, Calimlim B, Geng Z, Reyes Servin O, Rich PA.
    J Eur Acad Dermatol Venereol; 2019 Nov 25; 33(11):2168-2178. PubMed ID: 31304993
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis.
    Gordon KB, Duffin KC, Bissonnette R, Prinz JC, Wasfi Y, Li S, Shen YK, Szapary P, Randazzo B, Reich K.
    N Engl J Med; 2015 Jul 09; 373(2):136-44. PubMed ID: 26154787
    [Abstract] [Full Text] [Related]

  • 20. Etanercept biosimilar (recombinant human tumor necrosis factor-α receptor II: IgG Fc fusion protein) and methotrexate combination therapy in Chinese patients with moderate-to-severe plaque psoriasis: a multicentre, randomized, double-blind, placebo-controlled trial.
    Liu LF, Chen JS, Gu J, Xu JH, Jin HZ, Pang XW, Wang G, Yu C, Song ZQ, Guo ZP, Li W, Lai W, Cui PG, Chen M, Fang H, Lyu CZ, Li YZ, Sun Q, Xie HF, Liu XM, Gao XH, Shi YL, Zhao NQ, Zhang W, Zheng M.
    Arch Dermatol Res; 2020 Aug 09; 312(6):437-445. PubMed ID: 31873772
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.